Development and validation of the BMQ-AIR©: a screening tool for assessing patients’ treatment beliefs about switching to anti-inflammatory reliever (AIR) therapy
IntroductionDespite anti-inflammatory reliever (AIR) therapy now being the preferred treatment choice across all severities of asthma, many patients are still “attached” to their short-acting beta2-agonist (SABA) reliever, believing this to be the best way to control their asthma. To encourage indiv...
Guardado en:
| Autores principales: | , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Frontiers Media S.A.
2024-06-01
|
| Colección: | Frontiers in Pharmacology |
| Materias: | |
| Acceso en línea: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1351851/full |
| Etiquetas: |
Sin Etiquetas, Sea el primero en etiquetar este registro!
|